


Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

5 **Listing of Claims:**

1. (Cancelled)
2. (Cancelled)
3. (Original) A compound represented by Formula I:




10

Formula I

wherein the dashed lines indicate the presence or absence of a bond, the hatched wedges indicate the α (down) configuration, and the solid triangles indicate the β (up) configuration;

15 B is a single, double, or triple covalent bond;
 n is 0-6;
 X is CH₂, S or O;
 Y is any pharmaceutically acceptable salt of CO₂H, or CO₂R, CONR₂,
 20 CONHCH₂CH₂OH, CON(CH₂CH₂OH)₂, CH₂OR, P(O)(OR)₂, CONRSO₂R, SONR₂, or



R is H, C₁₋₆ alkyl or C₂₋₆ alkenyl;

R² and R³ are C₁₋₆ linear alkyl which may be the same or different, and may be bonded to each other such that they form a ring incorporating the carbon to which they are commonly attached;

5 R⁴ is hydrogen, R, C(=O)R, or any group that is easily removed under physiological conditions such that R⁴ is effectively hydrogen;

R⁵ is hydrogen or R;

R⁶ is


i) hydrogen;

10 ii) a linear or branched hydrocarbon containing between 1 and 8 carbon atoms, which may contain one or more double or triple bonds, or oxygen or halogen derivatives of said hydrocarbon, wherein 1-3 carbon or hydrogen atoms may be substituted by O or a halogen; or

iii) aryloxy, heteroaryloxy, C₃₋₈ cycloalkyloxy, C₃₋₈ cycloalkyl, C₆₋₁₀ aryl or

15 C₃₋₁₀ heteroaryl, wherein one or more carbons is substituted with N, O, or S; and which may contain one or more substituents selected from the group consisting of halogen, trihalomethyl, cyano, nitro, amino, hydroxy, C₆₋₁₀ aryl, C₃₋₁₀ heteroaryl, aryloxy, heteroaryloxy, C₁₋₆ alkyl, OR, SR, and SO₂R; and

the compound of Formula I is not a compound of Formula II



Formula II

20

wherein A is CO₂H, CO₂Me, or CO₂Et;

D is a single, double, or triple covalent bond;

E is a linear, branched, or cycloalkyl chain of 3 to 7 carbons, trifluoromethylbutyl, hydroxylalkyl, or CH_2R^7 wherein R^7 is phenyl, cyclopentyl, phenoxy, chlorophenoxy, propoxy, or $-\text{CH}_2\text{SCH}_2\text{CH}_3$;

J is hydrogen, R, C(=O)R, or any group that is easily removed under physiological


5 conditions such that R^4 is effectively hydrogen; and

G is H or CH_3 .

4. (Previously Amended) The compound of claim 3 wherein A is CO_2R^8 , wherein R^8 is any linear, branched, or cyclic alkyl group having from 3 to 6 carbons.

5. (Previously Amended) The compound of claim 3 which is further represented by

10 Formula III



Formula III

wherein Y is CO_2R , or any pharmaceutically acceptable salt of CO_2H .

6. (Previously Amended) The compound of claim 5 wherein R^6 is C_{6-10} aryl or C_{3-10} heteroaryl, wherein one or more carbons is substituted with N, O, or S; and which may

15 contain one or more substituents selected from the group consisting of halogen, trihalomethyl, cyano, nitro, amino, hydroxy, C_{1-6} alkyl, OR, SR, and SO_2R .

7. (Previously Amended) The compound of claim 6 wherein R^6 is naphthyl, benzofuranyl, or benzothienyl, which may contain one or more substituents selected from the group consisting of halogen, trihalomethyl, cyano, nitro, amino, hydroxy, C_{1-6} alkyl,

20 OR, SR, and SO_2R .


8. (Previously Amended) The compound of claim 7 wherein Y is CO_2H or CO_2Me .

9. (Previously Amended) The compound of claim 8 where R^6 is 3-chlorobenzothien-2-yl.

10. (Previously Amended) The compound of claim 9 where n is 2.

11. (Previously Amended) The compound of claim 10 where B is a single bond.

5 12. (Previously Amended) The compound of claim 3 which is further represented by Formula IV



Formula IV

wherein Y is CO_2R or any pharmaceutically acceptable salt of CO_2H ; and

10. R^6 is C_{6-10} aryl or C_{3-10} heteroaryl, wherein one or more carbons is substituted with N, O, or S; and which may contain one or more substituents selected from the group consisting of halogen, trihalomethyl, cyano, nitro, amino, hydroxy, C_{1-6} alkyl, OR, SR, and SO_2R .

13. (Previously Amended) The compound of claim 12 wherein Y is CO_2H or CO_2Me .

14. (Previously Amended) The compound of claim 13 wherein R^6 is phenyl.

15. (Previously Amended) The compound of claim 14 wherein B is a double bond.

16. (Previously Amended) The compound of claim 13 wherein R^6 is napthyl, benzofuranyl, or benzothienyl, which may contain one or more substituents selected from the group consisting of halogen, trihalomethyl, cyano, nitro, amino, hydroxy, C_{1-6} alkyl, OR, SR, and SO_2R .

20. 17. (Previously Amended) The compound of claim 16 wherein R^6 is 3-chlorobenzothien-2-yl.

18. (Previously Amended) The compound of claim 17 wherein B is a double or triple bond.

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (Previously Amended) The compound of claim 3 wherein said compound is

5 selected from the group consisting of

(3-{(1*R*,4*S*,5*S*)-5-(3-chloro-benzo[b]thiophen-2-yl)-3-hydroxy-pent-1-enyl]-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentylsulfanyl}-propylsulfanyl)-acetic acid methyl ester (21, 22);

(3-{(1*R*,4*S*,5*S*)-5-(3-chloro-benzo[b]thiophen-2-yl)-3-hydroxy-pent-1-enyl]-4-hydroxy-

10 3,3-dimethyl-2-oxo-cyclopentylsulfanyl}-propylsulfanyl)-acetic acid (23, 24);

(*Z*)-7-{(1*R*,4*S*,5*R*)-5-[(*E*)-5-(3-chloro-benzo[b]thiophene-2-yl)-3-hydroxy-pent-1-enyl]-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentyl}-hept-5-ynoic acid methyl ester (34, 35);

(*Z*)-7-{(1*R*,4*S*,5*R*)-5-[(*E*)-5-(3-chloro-benzo[b]thiophene-2-yl)-3-hydroxy-pent-1-enyl]-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentyl}-hept-5-ynoic acid (36,37);

15 (*Z*)-7-{(1*R*,4*S*,5*R*)-5-[(*E*)-5-(3-chloro-benzo[b]thiophene-2-yl)-3-hydroxy-pent-1-enyl]-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentyl}-hept-5-enoic acid methyl ester (38,39);

(*Z*)-7-{(1*R*,4*S*,5*R*)-5-[(*E*)-5-(3-chloro-benzo[b]thiophene-2-yl)-3-hydroxy-pent-1-enyl]-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentyl}-hept-5-enoic acid (40,41);

20 (*Z*)-7-[(1*R*,4*S*,5*R*)-4-Hydroxy-5-((*E*)-3-hydroxy-5-phenyl-pent-1-enyl)-3,3-dimethyl-2-oxo-cyclopentyl]-hept-5-enoic acid methyl ester (50,51)

(*Z*)-7-[(1*R*,4*S*,5*R*)-4-Hydroxy-5-((*E*)-3-hydroxy-5-phenyl-pent-1-enyl)-3,3-dimethyl-2-oxo-cyclopentyl]-hept-5-enoic acid (52,53)

(*Z*)-7-[(1*R*,4*S*,5*R*)-5-((*E*)-4-Benzo[b]thiophen-2-yl-3-hydroxy-but-1-enyl)-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentyl]-hept-5-enoic acid (54,55)

25 7-[(1*R*,4*S*,5*R*)-5-((*E*)-4-Benzo[b]thiophen-2-yl-3-hydroxy-but-1-enyl)-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentyl]-heptanoic acid (56,57)

(*Z*)-7-[(1*R*,4*S*,5*R*)-5-(4-Benzo[b]thiophen-2-yl-3-hydroxy-butyl)-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentyl]-hept-5-enoic acid (58,59)

(*Z*)-7-[(1*R*,4*S*,5*R*)-5-((*E*)-4-Benzo[b]thiophen-2-yl-3-hydroxy-but-1-enyl)-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentyl]-hept-5-enoic acid ethylamide (60,61)

(*Z*)-7-[(1*R*,4*S*,5*R*)-5-((*E*)-4-Benzo[b]thiophen-2-yl-3-hydroxy-but-1-enyl)-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentyl]-hept-5-enoic acid diethylamide (62,63)

(*Z*)-7-[(1*R*,4*S*,5*R*)-5-((*E*)-4-Benzo[b]thiophen-2-yl-3-hydroxy-but-1-enyl)-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentyl]-hept-5-enoic acid (2-hydroxy-ethyl)-amide (64,65)


5 (3*S*,4*R*,5*R*)-4-((*E*)-4-Benzo[b]thiophen-2-yl-3-hydroxy-but-1-enyl)-3-hydroxy-2,2-dimethyl-5-[(*Z*)-6-(1-H-tetrazol-5-yl)-hex-2-enyl]-cyclopentanone (66,67) (*Z*)-7-[(1*R*,4*S*,5*R*)-5-((*E*)-4-Benzo[b]thiophen-2-yl-3-hydroxy-but-1-enyl)-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentyl]-hept-5-enoic acid amide (68,69)

(*Z*)-7-[(1*R*,4*S*,5*R*)-5-((*E*)-4-Benzo[b]thiophen-2-yl-3-hydroxy-but-1-enyl)-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentyl]-hept-5-enoic acid methyl ester (70,71)

7-[(1*R*,4*S*,5*R*)-5-((*E*)-4-Benzo[b]thiophen-2-yl-3-hydroxy-but-1-enyl)-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentyl]-hept-5-ynoic acid methyl ester (72,73)

7-[(1*R*,4*S*,5*R*)-5-((*E*)-4-Benzo[b]thiophen-2-yl-3-hydroxy-but-1-enyl)-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentyl]-hept-5-ynoic acid (74,75).

15 23. (Previously Amended) The compound of claim 3 which is further represented by Formula XIII



Formula XIII


wherein B represents a single or double bond;

and R⁶ is napthyl, benzofuranyl, or benzothienyl, which may contain one or more

20 substituents selected from the group consisting of halogen, trihalomethyl, cyano, nitro, amino, hydroxy, C₁₋₆ alkyl, OR, SR, and SO₂R.

24. (Previously Amended) The compound of claim 23 wherein R⁶ is benzothien-2-yl.

25. (Previously Amended) The compound of claim 24 wherein Y is any pharmaceutically acceptable salt of CO_2H , or CO_2R , CONR_2 , $\text{CONHCH}_2\text{CH}_2\text{OH}$, $\text{CON}(\text{CH}_2\text{CH}_2\text{OH})_2$, or




5 26. (Previously Amended) The compound of claim 25 wherein the dashed line indicates the presence of a bond and B is a double bond.

27. (Previously Amended) The compound of claim 25 wherein the dashed line indicates the presence of a bond and B is a single bond.


28. (Cancelled)

10 29. (Previously Presented) The compound of claim 23 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

30. (Previously Presented) The compound of claim 23 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.